—
C+
C+ The full Closelook — membership. Open the C+ overview

Madrigal Pharmaceuticals Inc (MDGL) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Madrigal Pharmaceuticals Inc

MDGL in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease often called MASH. Its lead product, Rezdiffra, works by activating a thyroid hormone receptor in the liver to reduce fat build-up. The company is based in West Conshohocken, Pennsylvania, and was founded in 2016.
Where it sits in the stack
Madrigal carries no seat in Rubin or Halo, our indices for the AI build-out; it sits instead in the healthcare and biotechnology sleeve of the wider universe, outside the compute-and-chip chain the diary usually tracks.
Who it is priced against
No Closelook peer group is attached to this name; a comparator the market names on its own is Viking Therapeutics, another company working on MASH treatments.
Why Closelook tracks it
It carries a Closelook score, with momentum as its strongest reading; there is no index seat, no editions have quoted it, and its mention count in the diary stands at nil.
What the diary watches
The diary watches how sales of Rezdiffra develop and whether momentum in the shares holds up against the stock's distance from its recent high.

Madrigal Pharmaceuticals Inc (MDGL) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for MDGL, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against MDGL on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Madrigal Pharmaceuticals Inc (MDGL)?

Madrigal Pharmaceuticals Inc trades as MDGL on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-23.

Is MDGL in a Closelook index?

Not currently — Madrigal Pharmaceuticals Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

Where does MDGL trade against its moving averages?

Pullback inside an uptrend stack: Trades -1.9% vs the 50-day and +1.1% vs the 200-day average, 15.6% below the 52-week high and +31.8% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Madrigal Pharmaceuticals Inc do?

Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease often called MASH. Its lead product, Rezdiffra, works by activating a thyroid hormone receptor in the liver to reduce fat build-up. The company is based in West Conshohocken, Pennsylvania, and was founded in 2016. No Closelook peer group is attached to this name; a comparator the market names on its own is Viking Therapeutics, another company working on MASH treatments.

Where does Madrigal Pharmaceuticals Inc sit in the AI build-out?

Madrigal carries no seat in Rubin or Halo, our indices for the AI build-out; it sits instead in the healthcare and biotechnology sleeve of the wider universe, outside the compute-and-chip chain the diary usually tracks. It carries a Closelook score, with momentum as its strongest reading; there is no index seat, no editions have quoted it, and its mention count in the diary stands at nil.

What does this page show?

A live price chart with SMA overlays and drawing tools for MDGL, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.